VINORELBINE INHIBITS ONCOGENIC FUNCTIONS OF MKK3: A NEW THERAPEUTIC OPPORTUNITY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
Key facts
- Where
- Rome, OlaszországSee the site
- Phase
- 2. fázis
Where in Olaszország
- I.F.O. Istituti Fisioterapici OspitalieriRome, OlaszországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- I.F.O. Istituti Fisioterapici Ospitalieri
- Trial code
- EU 2024-519459-27-00
- Record updated
- 2025. május 9.
- Original description
Primary Objective. Objective Response Rate (ORR) according to RECIST 1.1 criteriaRead full original descriptionShow less
Primary Objective. Objective Response Rate (ORR) according to RECIST 1.1 criteria
Inclusion: histologically proven diagnosis of CRC; - measurable metastatic disease according to RECIST 1.1; - availability of histological specimens; - no evidence of brain or meningeal disease. Treated and clinically stable brain metastases are permitted; - age ≥ 18 years; - ECOG performance status = 0-2; - life expectancy > 3 months; - patients must have received all standard treatments indicated for metastatic disease (chemotherapy and/or targeted or immunological therapy) and have relapsed or progressed compared to a previous therapy. - if female of childbearing age, have a negative pregnancy test performed no more than 7 days before the start of study treatment; - If female of childbearing potential or male, agree to use adequate contraception (e.g., abstinence, intrauterine device, oral contraceptive, or double barrier method) based on investigators judgment; Childbearing patients must use two methods of contraception; - Adequate bone marrow, liver, and kidney function assessed within 14 days prior to the start of study treatment; - Patients able to understand the Italian language and to adhere to the study by signing, personally or by means of a designated witness, the informed consent (to trial and to data processing) prior to any study-specific procedures; - Patients must be fit for treatment and follow-up. - Investigators must ensure that enrolled patients in this trial will be available to provide complete documentation of treatment, toxicity, response assessment, and FU.
Exclusion: Patients with a history of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in situ cervical cancer, prostate cancer with stable PSA for ≥ 3 years, or other curatively treated solid tumors with no evidence of disease for ≥ 5 years; - Pregnant or breastfeeding women. - Patients receiving concomitant treatment with other anticancer therapies; - Patients with active or uncontrolled infections, or serious illnesses or medical conditions that would not allow that patient to be managed according to the protocol; - Patients with untreated and/or uncontrolled cardiovascular conditions and/or symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction in the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects) are not eligible; - Other concomitant investigational drugs. - Known intolerance to the study drug or any of the excipients. - Any pre-existing or current medical or other condition that in the opinion of the investigator(s) would preclude the participant from participating in this study.